Editorials

Umbilical cord blood banks in the UK

BMJ 2001; 323 doi: http://dx.doi.org/10.1136/bmj.323.7304.60 (Published 14 July 2001) Cite this as: BMJ 2001;323:60

Have proved their worth and now deserve a firmer foundation

  1. S J Proctor, professor of haematological medicine,
  2. A M Dickinson, senior lecturer in marrow transplant biology,
  3. T Parekh, research medical student,
  4. C Chapman, consultant in transfusion medicine
  1. University of Newcastle upon Tyne, Newcastle upon Tyne NE1 4LP
  2. Blood Transfusion Service, Newcastle upon Tyne NE2 4NQ

    Allogeneic stem cell transplantation has revolutionised the outcome for a wide range of malignant and non-malignant haematological conditions.1 Of the sources of stem cells, umbilical cord blood, obtained from the placenta directly after delivery, is enriched in stem cells and has a higher proliferative capacity than cells obtained from bone marrow and peripheral blood. 2 3 Like any blood product, however, stem cells from cord blood need an infrastructure for collecting, banking, and matching the donations.

    Several cord blood banks and registries have been formed internationally (four of them in the United Kingdom) which collect the cord blood products and perform cryopreservation, tissue typing, and viral assessment. These products can then be accessed after a search of the internet linked databases and the cryopreserved product transported to the transplant centre for use.

    Marrow engraftment can occur quite quickly after infusion of cord blood, although it may be delayed in some instances—this depends largely on the cell dose in the sample and the size of the recipient. In the largest series, reported by Rubinstein et al, 562 …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe